DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/rb2tpq/product_profiles) has announced the addition of the "Product Profiles: Autism Spectrum Disorders - Growing Interest in Underserved Market" report to their offering.
This report reviews current brands indicated for the treatment of autism spectrum disorders (ASDs) and key drugs in clinical development for the potential treatment of these conditions.
Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of irritability in children and adolescents with ASDs. Later, in 2009, the FDA approved Abilify for the same indication. In 2008, generic risperidone launched following Risperdal's US patent expiry.
Scope:
- Overview of marketed and pipeline drugs in clinical development for autism spectrum disorders.
- Analysis of the market positioning of each product approved for the treatment of autism spectrum disorders.
- Assessment of the strengths, weaknesses, opportunities, and threats for marketed and late-stage pipeline candidates.
- Summary of the clinical and commercial attractiveness for each of the marketed products.
- Insight from key opinion leaders on marketed and pipeline products.
Read more from the original source:
Research and Markets: Product Profiles: Autism Spectrum Disorders - Growing Interest in Underserved Market